NAMMIS | Documents & Publication | Drug Resistance | ITBN | FAQ | Contact Us | About Us |  Feedback|Home

KALA-AZAR OR VISCERAL LEISHMANIASIS

 

What is Kala-azar?Photo

  • Kala-azar is a slow progressing indigenous disease caused by a protozoan parasite of genus Leishmania

  • In India Leishmania donovani  is the only parasite causing this disease

  • The parasite primarily infects reticuloendothelial system and may be found in abundance in bone marrow, spleen and liver.

  • Post Kala-azar Dermal Leishmaniasis (PKDL) is a condition when Leishmania donovani invades skin cells, resides and develops there and manifests as dermal leisions. Some of the kala-azar cases manifests PKDL after a few years of treatment. Recently it is believed that PKDL may appear without passing through visceral stage. However, adequate data is yet to be generated on course of PKDL manifestation

What are Signs & Symptoms of Kala-Azar?Photo

  • Recurrent fever intermittent or remittent with often double rise

  • loss of appetite, pallor and weight loss with progressive emaciation

  • weakness

  • Splenomegaly – spleen enlarges rapidly to massive enlargement, usually soft and nontender

  • Liver – enlargement not to the extent of spleen, soft, smooth surface, sharp edge

  • Lymphadenopathy – not very common in India

  • Skin – dry, thin and scaly and hair may be lost. Light coloured persons show grayish discolouration of the skin of hands, feet, abdomen and face which gives the Indian name Kala-azar meaning “Black fever”

  • Anaemia – develops rapidly

Anaemia with emaciation and gross splenomegaly produces a typical appearance of the patients

What is Post Kala-Azar Dermal Leishmaniasis (PKDL)?

Post Kala-azar Dermal Leishmaniasis is a condition in which Leishmania donovani parasites are found in skin.  PKDL develops in some of the Indian kala-azar patients usually 1-2 years or more following recovery of Kala-azar; less commonly without suffering from Kala-azar 

What are Signs & Symptoms of PKDL?Photo

Types of morphological lesions: 

  • Early hypopigmented macules similar to macular lesions of Lepromatous Leprosy but normally less than 1 cm. Usually occur on face but can affect any part of the body.

  • Later (after a variable period of months or years) diffuse nodular lesions on those macules

  • Erythematous butterfly rash which may be aggravated by exposure to Sunlight; an early sign of PKDL

  • Erythematous papules and nodules which usually occur on face, especially the chin.

  • Lesions progressive over many years , seldom heal spontaneously

Rare manifestations of PKDL include:

  • Multiple lesions coalesce to form larger plaque type lesions

  • Verrucous lesions (hands and feet)

  • Papillomatous lesions (on muzzle area of face, nose, chin, and lips)

  • Hypertrophic lesions (eyelids, nose and lips)

  • Xanthematous rash (orange plaque on axillary fold, cubital fossae, inner thighs, outer canthus of the eye and perioral)

  • Pityriasis rosea like lesions

HIV and Kala-azar co-infection

  • Visceral leishmaniasis (VL) has emerged as an opportunistic infection in HIV and other immunosuppressed patients

  • More than 1000 cases of HIV and VL are reported from 25 countries. However, in India yet not a serious problem

  • VL may be first Opportunistic Infection in asymptomatic HIV-I infected person

  • Also occurs in advanced stage of AIDS

  • All co-infected patients are not symptomatic

  • Diagnosis may be altered because symptoms may be of short duration; fever and spleen may not be marked; Leishmania antibodies may be undetectable.

  • However peripheral blood smears of buffycoat and blood culture may yield good results

  • Response to treatment is poor; drug side effects may be more and relapses may be common

How Kala-azar is transmitted?Photo

  • Kala-azar is a vector borne disease
  • Sandfly of genus Phlebotomus argentipes are the only known vectors of kala-azar in India
  • Indian Kala-azar has a unique epidemiological feature of being Anthroponotic; human is the only known reservoir of infection
  • Female snadflies pick up parasite (Amastigote or LD bodies)while feeding on an infected human host.
  • Parasite undergo morphological change to become flagellate (Promastigote or Leptomonad), development and multiplication in the gut of sandflies and move to mouthparts
  • Healthy human hosts get infection when an infective sandfly vector bites them

Kala-azar Vector in India

  • There is only one sandfly vector of Kala-azar in India Phlebotomus aregentipes

  • Sandflies are small insects, about one fourth of a mosquito.  The length of a snadfly body ranges from 1.5 to 3.5 mm.
  • Adult is a small fuzzy, delicately proportionate fly with erect large wings. The entire body including wings is heavily clothed with long hairs.
  • Life cycle consists of egg, four instars of larvae, pupa and adult. The whole cycle takes more than a month, however, duration depends on temperature and other ecological conditions
  • They prefer high relative humidity, warm temperature, high subsoil water and abundance of vegetation.
  • Sandflies breed in favourable micro-climatic conditions in places with high organic matter that serve as food for larvae
  • These are ecologically sensitive insects, fragile and cannot withstand desiccation

How Kala-azar is Diagnosed?

  • Clinical:
    • A case of fever of more than 2 weeks duration not responding to antimalarials and antibiotics. Clinical laboratory findings may include anaemia, progressive leucopenia thrombocytopenia and hypergammaglobulinemia
  • Laboratory: 
    • Serology tests: Variety of tests are available for diagnosis of Kala-azar. The most commonly used tests based on relative sensitivity; specificity and operationally feasibility include Direct Agglutination Test (DAT), rk39 dipstick and ELISA. However all these tests detect IgG antibodies that are relatively long lasting. Aldehyde Test is commonly used but it is a non-specific test. IgM detecting tests are under development and not available for field use.
    • Parasite demonstration in bone marrow/spleen/lymphnode aspiration or in culture medium is the confirmatory diagnosis. However, sensitivity varies with the organ selected for aspiration. Though spleen aspiration has the highest sensitivity and specificity (considered gold standard) but a skilled professional with appropriate precaustions can perform it only at a good hospital facility.
  • Differential Diagnosis:
    • Typhoid

    •  Miliary tuberculosis

    • Malaria  

    • Brucellosis

    • Amoebic liver abscess 

    • Infectious mononucleosis

    • Lymphoma, Leukemia

    • Tropical splenomegaly

    • Portal hypertension

What is the Treatment of Kala-azar?

  • Kala-azar Drugs available in India

    • Sodium Stibogluconate (indigenous manufacture, registered for use & sale)

    • Pentamidine Isethionate: (imported, registered for use)
    • Amphotericin B: (indigenous manufacture, registered for use and sale)
    • Liposomal Amphotericin B: (indigenous manufacture & import, registered for use and sale)
    • Miltefosine (imported/ registered for use & sale)
  • Drug Policy under Kala-azar Elimination Programme as per recommendations of Expert Committee (2000) – (This drug policy is under review)
  • First Line Drugs

      A.  Short Term

  • Areas with SSG sensitivity >90%

                    -  SSG IM/IV 20mg/kg/day X 30 days

  • Areas with SSG sensitivity <90%

                    -  Amphotericin B 1mg/kg b.w. IV infusion daily or alternate day for 15-20 infusions. Dose can be increased

                        in patients with incomplete response with 30 injections

      B.  Long Term

  • Areas with high level of SSG resistance (>20%)

                   -   Miltefosine 100 mg daily x 4 weeks (after phase III studies completed with proven safety & efficacy)

  • Areas with SSG sensitivity >80%

                   -   SSG IM/IV 20mg/kg/day X 30 days

                   -   Miltefosine 100 mg daily x 4 weeks (after phase III studies completed with proven safety & efficacy)

  • Second Line Drugs

      A. SSG Failures

                  -   Amphotericin B 1mg/kg b.w. IV infusion daily or alternate day for 15-20 infusions. Dose can be increased in patients

                      with incomplete response with 30 injections

     B.  SSG and Miltefosine Failures

                        -    Liposomal Amphotericin B (when final results are available with proven efficacy and safety)

Treatment of PKDL

  •  SSG in usual dosages for KA could be given up to 120 days

  • Repeated 3-4 courses of Amphotericin B can be given in patients failing SSG treatment

What is the extent of problem of Kala-azar in India? 

  • Endemic in eastern States of India namely Bihar, Jharkhand, Uttar Pradesh and West Bengal
  • 48 districts endemic; sporadic cases reported from a few other districts
  • Estimated 165.4 million population at risk in 4 states
  • Mostly poor socio-economic groups of population primarily living in rural areas are affected

Kala-azar Control Efforts in India 

  • An organized centrally sponsored Control Programme launched in endemic areas in 1990-91
  • Government of India provided kala-azar medicines, insecticides and technical support and the State governments implemented the programme through primary health care system and district/zonal and State malaria control organizations and provided other costs involved in strategy implementation
  • Programme strategy included:

      -    Vector control through IRS with DDT up to 6 feet height from the ground twice annually

      -   Early Diagnosis and Complete treatment

      -   Information Education Communication

     -   Capacity Building

  • Programme intensified in 1991-92 which led to improved case registration through primary health care system
  • Programme Achievemnets

     –   Within 3 years of intensification (1995 as compared to 1992)

  •  70.66% decline in annual incidence

  •  80.48% decline in deaths

      -   By 2003 as compared to 1992

  • 76.38% decline in incidence

  • 85.20% decline in deaths

KALA-AZAR SITUATION IN INDIA SINCE 2002

Sl. No. State 2002 2003 2004 2005 2006 (P) 2007(P) upto June
    Cases Deaths Cases Deaths Cases Deaths Cases Deaths Cases Deaths Cases Deaths
1 Bihar 9684 160 13960 187 17324 107 21797 124 29711 162 18882 81
2 W. Bengal 1592 5 1487 7 2876 24 2706 15 1843 10 1240 8
3 U.P. 32 1 34 1 34 2 73 2 83 0 13 1
4 Jharkhand 758 0 2607 5 4028 14 6578 12 7508 11 2599 10
5 Delhi 74* 2* 126* 10* 78* 9* 62* 4* 31* 4* 15 1
6 Assam 0 0 0 0 0 0 1 0 0 0    
7 Gujarat 0 0 0 0 0 0 0 0 2 0 2 0
  INDIA 12140 168 18214 210 24340 156 31217 157 39178 187 22751 101

Note: -  *  =  Imported,               (P) = Provisional 

KALA-AZAR ELIMINATION INITIATIVE

  • National Health Policy Goal: Kala-azar Elimination by the year 2010
  • Elimination Programme is 100 per cent Centrally Supported (except regular staff of State governments & infrastructure)
  • In addition to kala-azar medicines and insecticides, cash assistance is being provided to endemic state s since December 2003 to facilitate effective strategy implementation by states

 

 

 

Home

 

National Vector Borne Disease Control Programme, 22, Shamnath Marg, Delhi - 110054.